ABUS icon

Arbutus Biopharma
ABUS

Overview Fund Activity

126 hedge funds and large institutions have $88.4M invested in Arbutus Biopharma in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 5 closing their positions.

Holders
126
Holders Change
+14
Holders Change %
+12.5%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
44
Reduced
33
Closed
5
Calls
$1.95M
Puts
$1.25M
Net Calls
+$696K
Net Calls Change
-$1.48M

Top Buyers

1
TSC
1
Two Seas Capital
New York
$10.8M
2
OMC
2
Oasis Management Company
Cayman Islands
$1.96M
3
Marshall Wace
3
Marshall Wace
United Kingdom
$751K
4
Hudson Bay Capital Management
4
Hudson Bay Capital Management
Connecticut
$9.48M
5
Geode Capital Management
5
Geode Capital Management
Massachusetts
$3.84M

Top Sellers

1
BC
1
Brookfield Corp
Ontario, Canada
$0
2
Millennium Management
2
Millennium Management
New York
$6.7M
3
Assenagon Asset Management
3
Assenagon Asset Management
Luxembourg
$3.62M
4
Two Sigma Advisers
4
Two Sigma Advisers
New York
$0
5
Simplex Trading
5
Simplex Trading
Illinois
$77K
Name Holding Trade Value Shares
Change 		Shares
Change %
Two Sigma Advisers
126
Two Sigma Advisers
New York
– -$175K -64,400 Closed
VF
127
Virtu Financial
New York
– -$143K -52,722 Closed
SPC
128
Sigma Planning Corp
Michigan
– -$30K -11,000 Closed
SIAP
129
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
– -$11K -4,000 Closed
2 3 4 5
6